In this issue:
Low rates of radiographic spinal progression with ixekizumab for axSpA
Patient-reported axial symptoms associated with higher PsA disease activity
DISCOVER-2: long-term guselkumab elicits durable joint and skin improvements
Biologic therapy during pregnancy increases risk of adverse outcomes
Differentiating axSpA from mechanical back pain by sacroiliac joint MRI
Morphological characteristics of sacroiliac joint lesions in axSpA
Low levels of physical activity in patients with inflammatory joint disease
Diagnosis and treatment of AS in the US
Pain catastrophising negatively impacts quality of life
Switching between IL-17 antagonists may elicit response in non-responders
Please login below to download this issue (PDF)